Henry Nagai Contributes to Biomedical HIV Prevention Framework

Henry Nagai, chief of party for our USAID Strengthening the Care Continuum Project in Ghana, was a contributor to the Biomedical Prevention Implementation Collaborative’s Biomedical HIV Prevention Framework. The framework addresses gaps in planning coordination for product introduction in the rapidly evolving HIV prevention realm. The aim is to shorten the time from regulatory approval to introduction and scale-up in low- and middle-income countries (LMICs).

The introduction of oral pre-exposure prophylaxis (PrEP) offered lessons and opportunities for improvement: it took quite a bit of time to get from product release to roll out in many LMICs. The Biomedical HIV Prevention Framework seeks to avoid similar delays in future. Given that the dapivirine vaginal ring, the long-acting injectable cabotegravir (CAB-LA), and other HIV prevention biomedical tools are in the pipeline, this framework is a valuable contribution to the field.

The framework includes use cases for donors, product manufacturers, modelers, and clinical researchers.

Click here to access the Biomedical HIV Prevention Framework.